Drug found to be effective in difficult-to-treat autoimmune blood disorder


Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

Nintendo’s first clip from ‘The Super Mario Bros. Movie’ shows off the Mushroom Kingdom

Previous article

Overexpression of lncRNA MVIH may serve as a potential diagnostic biomarker in cervical cancer

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations